Ocugen (OCGN) Stock News

Ocugen (NASDAQ: OCGN) reported significant progress in Q2 2025 across its gene therapy pipeline. The company initiated dosing in the OCU410ST Phase 2/3 GARDian3 pivotal trial for Stargardt disease and continues actively dosing patients in the OCU400 Phase 3 liMeliGhT trial for retinitis pigmentosa, targeting 2026 BLA filing.

Key developments include a binding term sheet for Korean rights to OCU400 worth up to $11 million in upfront and milestone payments, plus 25% royalties. The company also announced a strategic reverse merger of OrthoCellix with Carisma Therapeutics to unlock value from its NeoCart technology. Financial results show $27.3 million in cash as of June 30, 2025, providing runway into Q1 2026, with a quarterly net loss of $0.05 per share.

The company's OCU410 demonstrated promising Phase 1 results, showing 23% slower geographic atrophy lesion growth and a 2-line gain in visual acuity.

Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, has announced significant additions to its leadership structure. The company has expanded its Retina Scientific Advisory Board (SAB) with three renowned retinal surgeons: Dr. Jeffrey S. Heier, Dr. Peter K Kaiser, and Dr. Arshad M. Khanani, joining existing members under the leadership of SAB chair Dr. Lejla Vajzovic.

Additionally, Ocugen has strengthened its executive team with two key appointments: Dr. Vijay Tammara as Chief Development Officer, bringing over 32 years of global regulatory leadership and experience with nine Marketing Authorization approvals, and Abhi Gupta as Executive Vice President of Commercial and Business Development, with extensive experience in gene therapy commercialization and a track record at companies like Pfizer and Johnson & Johnson.

These appointments align with Ocugen's strategic goal of pursuing three Biologics License Applications (BLAs) in the next three years.

Ocugen (NASDAQ: OCGN) has announced the dosing of its first patient in the Phase 2/3 GARDian3 pivotal confirmatory trial for OCU410ST, a modifier gene therapy candidate for Stargardt disease. The trial follows encouraging Phase 1 results that showed 48% slower lesion growth and a statistically significant 2-line gain in visual acuity at 12-month follow-up.

The Phase 2/3 study will enroll 51 participants, with 34 receiving a one-time subretinal injection of OCU410ST and 17 serving as untreated controls. The therapy targets ABCA4-associated retinopathies, affecting approximately 100,000 patients in the U.S. and Europe. Ocugen plans to submit a Biologics License Application (BLA) in 2027, based on one-year follow-up data.

Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, has scheduled its Q2 2025 earnings conference call for August 1, 2025, at 8:30 a.m. ET. The company will release its financial results before the market opens on the same day.

Investors can access the call via U.S. dial-in (800-715-9871) or international dial-in (646-307-1963) using conference ID 9627149. A webcast will be available on Ocugen's investor relations website, with a replay accessible for approximately 45 days after the event.

Carisma Therapeutics and OrthoCellix have entered into a definitive merger agreement to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The combined entity will prioritize the development of OrthoCellix's Phase 3-ready NeoCart®, an autologous cartilage implant technology for knee cartilage defects. Under the agreement, OrthoCellix will merge with Carisma's subsidiary, with OrthoCellix stockholders and financing participants owning approximately 90% of the combined company, while existing Carisma stockholders will retain 10%. The merger includes a concurrent $25.0 million financing to fund NeoCart's Phase 3 trial. The combined company will be renamed OrthoCellix, Inc. and trade under the ticker 'OCLX'. The transaction is expected to close in second half of 2025, subject to stockholder approvals and regulatory requirements.

Ocugen (NASDAQ: OCGN) has received FDA clearance for its IND amendment to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy for Stargardt disease. The therapy, which previously received Rare Pediatric Disease and Orphan Drug Designations, showed promising Phase 1 results with 48% slower lesion growth and significant visual improvement at 12 months. The Phase 2/3 trial will enroll 51 participants, with 34 receiving OCU410ST and 17 serving as controls. The study aims to evaluate reduction in atrophic lesion size and improvements in visual acuity. The therapy addresses a significant unmet need, targeting a condition affecting approximately 100,000 patients in the U.S. and Europe combined. Ocugen plans to submit a Biologics License Application (BLA) in 2027.

Ocugen (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced its participation in the 2025 BIO International Convention in Boston from June 16-19, 2025. CEO Dr. Shankar Musunuri will present at multiple sessions, including a company presentation and panel discussions on clinical program optimization and regulatory landscape. The company recently secured exclusive Korean rights for OCU400 through a partnership agreement and achieved key milestones, including FDA alignment for Phase 2/3 pivotal trial and Rare Pediatric Disease Designation for OCU410ST. Notably, enrollment is nearly complete for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application by mid-2026.

Ocugen (NASDAQ: OCGN) has signed a binding term sheet for licensing OCU400, its modifier gene therapy for retinitis pigmentosa (RP), to a leading Korean pharmaceutical company. The agreement includes upfront fees and near-term development milestone payments of up to $11 million, plus sales milestones of $1 million for every $15 million in net sales. Ocugen will receive a 25% royalty on net sales and will manufacture the commercial supply. The deal targets approximately 15,000 RP patients in Korea. OCU400 is currently in Phase 3 clinical development with a planned Biologics License Application filing by mid-2026. This regional licensing strategy aligns with Ocugen's business development approach to partner with established companies while preserving rights in larger markets.

Ocugen (NASDAQ: OCGN) has received Rare Pediatric Disease Designation (RPDD) from the FDA for OCU410ST, its gene therapy treatment for ABCA4-associated retinopathies, including Stargardt disease. This designation applies to serious diseases affecting children under 18 and fewer than 200,000 people in the U.S. The treatment already holds Orphan Drug designations from both FDA and European Medicines Agency. Approximately 100,000 people in the U.S. and Europe combined are affected by Stargardt disease. If the Priority Review Voucher (PRV) program is reauthorized, Ocugen could receive a voucher worth approximately $100 million. The company plans to begin Phase 2/3 pivotal confirmatory trials soon, targeting a Biologics License Application (BLA) filing in 2027.